Search Within

Paul Chapman

Formats
  1. Journal Article (206)
  2. Meeting Abstract (109)
  3. Book Section (8)
  4. Conference Paper (1)
  5. Editorial (1)
  6. Research Letter (1)
  7. Review (1)
Groups
  1. Alan and Sandra Gerry Metastasis and Tumor Ecosystems Center (327)
  2. Department of Medicine (327)
  3. Melanoma and Immunotherapeutics Service (327)
  4. Solid Tumor Oncology Division (327)
  5. GSK Faculty (133)
  6. Melanoma Disease Management Team (93)

More Groups

People
  1. Jedd Wolchok (107)
  2. Katherine Panageas (77)
  3. Alan Houghton (60)
  4. Michael Postow (55)
  5. Margaret Callahan (50)
  6. Alexander Shoushtari (46)

More People

Years
  1. 2025 (1)
  2. 2024 (2)
  3. 2023 (8)
  4. 2022 (2)
  5. 2021 (9)
  6. 2020 (8)

More Years

Publications
  1. Journal of Clinical Oncology (88)
  2. Clinical Cancer Research (29)
  3. Cancer Research (15)
  4. Proceedings of the American Association for Cancer Research Annual Meeting (13)
  5. New England Journal of Medicine (11)
  6. Melanoma Research (10)

More Publications

Publishers
  1. American Society of Clinical Oncology (94)
  2. American Association for Cancer Research (60)
  3. Elsevier Inc. (22)
  4. Lippincott Williams & Wilkins (19)
  5. Wiley Blackwell (19)
  6. Oxford University Press (13)

More Publishers

Results (327)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Vemurafenib sensitivity skin reaction after ipilimumab
    Journal Article

    Harding, J. J.; Pulitzer, M.; Chapman, P. B.
    New England Journal of Medicine (2012)

    Fulltext@MSK | Save
  • RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors
    Journal Article

    Su, F.; Viros, A.; Milagre, C.; Trunzer, K.; Bollag, G.; Spleiss, O.; Reis-Filho, J. S.; Kong, X.; Koya, R. C.; Flaherty, K. T.; more...
    New England Journal of Medicine (2012)

    Fulltext@MSK | Save
  • Phase III randomized, open-label, multicenter trial (BRIM3) comparing BRAF inhibitor vemurafenib with dacarbazine (DTIC) in patients with (V600E)BRAF-mutated melanoma
    Meeting Abstract

    Chapman, P. B.; Hauschild, A.; Robert, C.; Larkin, J. M. G.; Haanen, J. B. A. G.; Ribas, A.; Hogg, D.; O'Day, S.; Ascierto, P. A.; Testori, A.; more...
    Journal of Clinical Oncology (2011)

    Fulltext@MSK | Save
  • Molecular analyses from a phase I trial of vemurafenib to study mechanism of action (MOA) and resistance in repeated biopsies from BRAF mutation-positive metastatic melanoma patients (pts)
    Meeting Abstract

    McArthur, G. A.; Ribas, A.; Chapman, P. B.; Flaherty, K. T.; Kim, K. B.; Puzanov, I.; Nathanson, K. L.; Lee, R. J.; Koehler, A.; Spleiss, O.; more...
    Journal of Clinical Oncology (2011)

    Fulltext@MSK | Save
  • Presence of frequent underlying RAS mutations in cutaneous squamous cell carcinomas and keratoacanthomas (cuSCC/KA) that develop in patients during vemurafenib therapy
    Meeting Abstract

    Lacouture, M. E.; Chapman, P. B.; Ribas, A.; Sosman, J. A.; McArthur, G. A.; Flaherty, K. T.; Kim, K. B.; Puzanov, I.; Nolop, K. B.; Joe, A. K.; more...
    Journal of Clinical Oncology (2011)

    Fulltext@MSK | Save
  • Pattern and outcome of disease progression in phase I study of vemurafenib in patients with metastatic melanoma (MM)
    Meeting Abstract

    Kim, K. B.; Flaherty, K. T.; Chapman, P. B.; Sosman, J. A.; Ribas, A.; McArthur, G. A.; Amaravadi, R. K.; Lee, R. J.; Nolop, K. B.; Puzanov, I.
    Journal of Clinical Oncology (2011)

    Fulltext@MSK | Save
  • An in-frame deletion in the N-terminal regulatory domain of BRAF(V600E) causes resistance to the RAF inhibitor PLX4032
    Meeting Abstract

    Poulikakos, P. I.; Persaud, Y.; Gabay, M. T.; Janakiraman, M.; Joseph, E. W.; Pratilas, C. A.; Chapman, P. B.; Rosen, N.; Solit, D. B.
    Cancer Research (2011)

    Fulltext@MSK | Save
  • Treatment of locally recurrent mucosal melanoma with topical imiquimod
    Journal Article

    Smyth, E. C.; Flavin, M.; Pulitzer, M. P.; Gardner, G. J.; Costantino, P. D.; Chi, D. S.; Bogatch, K.; Chapman, P. B.; Wolchok, J. D.; Schwartz, G. K.; more...
    Journal of Clinical Oncology (2011)

    Fulltext@MSK | Save
  • RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E)
    Journal Article

    Poulikakos, P. I.; Persaud, Y.; Janakiraman, M.; Kong, X.; Ng, C.; Moriceau, G.; Shi, H.; Atefi, M.; Titz, B.; Gabay, M. T.; more...
    Nature (2011)

    Fulltext@MSK | Save
  • Memorial Sloan-Kettering Cancer Center (MSKCC) single-institutional vulvovaginal mucosal melanoma (VVMM) experience from 1995-2010
    Meeting Abstract

    Smyth, E. C.; Flavin, M.; Barbi, A.; Bogdatch, K.; Wolchok, J. D.; Chapman, P. B.; Gardner, G. J.; Leitao, M. M.; Schwartz, G. K.; Carvajal, R. D.
    European Journal of Cancer (2011)

    Fulltext@MSK | Save